Journal
DIABETES & METABOLISM
Volume 43, Issue -, Pages 2S28-2S33Publisher
MASSON EDITEUR
DOI: 10.1016/S1262-3636(17)30070-8
Keywords
Steatosis; GLP-1 receptor agonists; type 2 diabetes; Non-alcoholic fatty liver disease; Fibrosis
Categories
Funding
- AstraZeneca/Bristol-Myers Squibb
- Bayer Pharma
- Kowa
- Lilly
- Merck Sharp Dohme
- Novartis
- Novo Nordisk
- Sanofi
- Servier
- Takeda
Ask authors/readers for more resources
Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed. (C) 2017 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available